Unknown

Dataset Information

0

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.


ABSTRACT: After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8+ T cells were characterized by bulk T-cell-receptor (TCR) repertoire sequencing and combined single-cell RNA and TCR sequencing. In patients mounting an immune response to the vaccine, a common SYE(N)E TCR motif known to bind CMVpp65 was detected. CMV-peptide-vaccination-responder patients had TCR features distinct from those of non-responders. In a non-responder patient, a monoclonal inflammatory T-cell response was detected upon CMV reactivation. The identification of vaccine-induced CMV-reactive TCRs motifs might facilitate the development of cellular therapies for patients wait-listed for kidney transplantation.

SUBMITTER: Bunse L 

PROVIDER: S-EPMC8835207 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.

Bunse Lukas L   Sommerer Claudia C   Tan Chin Leng CL   Korell Felix F   Schmitt Anita A   Hückelhoven-Krauss Angela A   Neuber Brigitte B   Mertens Thomas T   Platten Michael M   Green Edward W EW   Zeier Martin M   Schmitt Michael M  

International journal of molecular sciences 20220118 3


After solid-organ transplantation, reactivation of the cytomegalovirus (CMV) is often observed in seronegative patients and associated with a high risk of disease and mortality. CMV-specific T cells can prevent CMV reactivation. In a phase 1 trial, CMV-seronegative patients with end-stage renal disease listed for kidney transplantation were subjected to CMV phosphoprotein 65 (CMVpp65) peptide vaccination and further investigated for T-cell responses. To this end, CMV-specific CD8<sup>+</sup> T c  ...[more]

Similar Datasets

| S-EPMC7915922 | biostudies-literature
| S-EPMC6366655 | biostudies-literature
| S-EPMC4650765 | biostudies-literature
| S-EPMC8006424 | biostudies-literature
| S-EPMC3041771 | biostudies-literature
| S-EPMC10954330 | biostudies-literature
| S-EPMC3634158 | biostudies-literature
| S-EPMC11760718 | biostudies-literature
| S-EPMC8573716 | biostudies-literature
| S-EPMC10951402 | biostudies-literature